AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37497674 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ischemic postconditioning (IPostC) with 4 cycles of 5-minute ischemia followed by 5-minute reperfusion
Number of subjects: 18
Study 37497674 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ischemic postconditioning (IPostC) in dogs
Number of subjects: 18
Study 37497675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for at least 24 hours
Number of subjects: 364
Study 37497675 — intervention group
Group type: EXPERIMENTAL
Intervention: Time between stroke diagnosis and initiation of mechanical ventilation >1 day
Number of subjects: 364
Study 37497675 — intervention group
Group type: EXPERIMENTAL
Intervention: Various ICU admission variables
Number of subjects: 364
Study 37497675 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent physical and psychological problems at 1 year
Number of subjects: 364
Study 37497816 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous ablation and compression
Number of subjects: 506
Study 37497816 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 506
Study 37497816 — intervention group
Group type: COMPARATOR
Intervention: Compression with deferred endovenous treatment
Number of subjects: 506
Study 37497888 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN124 (1.0, 3.0, and 4.5 mg/kg)
Number of subjects: 24
Study 37497888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 37497888 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN124
Number of subjects: 24
Study 37497921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemoimmunotherapy and targeted treatment
Number of subjects: 0
Study 37497921 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapies (chemoimmunotherapy or targeted combinations)
Number of subjects: 0
Study 37497921 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL Treatment-Infection Model (machine learning-based algorithm)
Number of subjects: 0
Study 37498105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of silkworm pupae extract (SWP) per day plus regular exercise (n=27)
Number of subjects: 54
Study 37498105 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus regular exercise (n=27)
Number of subjects: 54
Study 37498255 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR (Cardiac Magnetic Resonance) imaging
Number of subjects: 0
Study 37498313 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Reverse Second Dorsal Metacarpal Artery Flap (MRSDMAF)
Number of subjects: 31
Study 37498313 — intervention group
Group type: COMPARATOR
Intervention: Modified Cross-Finger Flap (MCFF)
Number of subjects: 31
Study 37498313 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor site of MRSDMAF
Number of subjects: 31
Study 37498369 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (3 × 10^9 CFU of Lactobacillus and Bifidobacterium species)
Number of subjects: 24
Study 37498369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 37498415 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Number of subjects: 87
Study 37498415 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 87
Study 37498415 — intervention group
Group type: COMPARATOR
Intervention: Control (no active intervention)
Number of subjects: 87
Study 37498415 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 87
Study 37498442 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung extubation strategy
Number of subjects: 69
Study 37498442 — intervention group
Group type: COMPARATOR
Intervention: Conventional extubation strategy
Number of subjects: 69
Study 37498457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal temperature-modulating device (tnTMD)
Number of subjects: 40
Study 37498457 — intervention group
Group type: COMPARATOR
Intervention: Surface cooling temperature-modulating devices (sTMDs)
Number of subjects: 40
Study 37498488 — intervention group
Group type: EXPERIMENTAL
Intervention: IV posaconazole
Number of subjects: 10
Study 37498596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant weekly
Number of subjects: 100
Study 37498596 — intervention group
Group type: COMPARATOR
Intervention: Fosaprepitant every 3 weeks
Number of subjects: 100
Study 37498603 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week exercise program (3 to 5 sessions/week, 90 min/session) of aerobic plus resistance training
Number of subjects: 92
Study 37498603 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week exercise program
Number of subjects: 92
Study 37498603 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 92
Study 37498650 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous movement-to-music (M2M) program
Number of subjects: 30
Study 37498650 — intervention group
Group type: EXPERIMENTAL
Intervention: M2M Live (switch) or individualized behavioral coaching (augmented with the asynchronous M2M program)
Number of subjects: 30
Study 37498650 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation through semistructured interviews
Number of subjects: 30
Study 37498661 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Public Health Nurse-Delivered Group Cognitive Behavioral Therapy
Number of subjects: 0
Study 37498661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37498669 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Positive
Number of subjects: 646
Study 37498669 — intervention group
Group type: COMPARATOR
Intervention: FAU
Number of subjects: 646
Study 37498716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Diabetes Complications Questionnaire (FDCQ)
Number of subjects: 0
Study 37498716 — intervention group
Group type: EXPERIMENTAL
Intervention: FDCQ cutoff score for elevated FDC set at ≥30 in the 15-item FDCQ
Number of subjects: 0
Study 37498821 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus up to 16 sessions of physical therapy
Number of subjects: 0
Study 37498821 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 37498909 — intervention group
Group type: EXPERIMENTAL
Intervention: GIR score≤3 (initial functional disability)
Number of subjects: 97
Study 37499521 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib plus erlotinib (erlotinib 100 mg daily and binimetinib 15 mg BID × 5 days/week)
Number of subjects: 43
Study 37499521 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib plus erlotinib
Number of subjects: 43
Study 37499670 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily
Number of subjects: 543
Study 37499670 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily
Number of subjects: 543
Study 37499670 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus rivoceranib
Number of subjects: 543
Study 37499670 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 543
Study 37499679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Alhydrogel (40 μg)
Number of subjects: 200
Study 37499679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel (47 μg)
Number of subjects: 200
Study 37499679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel (47 μg) plus Pfs230D1-EPA/Alhydrogel (40 μg)
Number of subjects: 200
Study 37499679 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Twinrix or Menactra)
Number of subjects: 200
Study 37499853 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory training with the anchor system
Number of subjects: 80
Study 37499853 — intervention group
Group type: COMPARATOR
Intervention: Multisensory training without the anchor system
Number of subjects: 80
Study 37499870 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 37499991 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pushing
Number of subjects: 1618
Study 37499991 — intervention group
Group type: COMPARATOR
Intervention: Intensive pushing
Number of subjects: 1618
Study 37500008 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based mindful physical activity (yoga) intervention
Number of subjects: 200
Study 37500008 — intervention group
Group type: COMPARATOR
Intervention: Prenatal education control group
Number of subjects: 200
Study 37500072 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 275
Study 37500072 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness resection device (FTRD)
Number of subjects: 275
Study 37500120 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 34
Study 37500236 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based caries prevention program
Number of subjects: 0
Study 37500236 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment years (comparator schools)
Number of subjects: 0
Study 37500273 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan mouthwash gargle, used morning and night, and around sexual activities for 6 months.
Number of subjects: 40
Study 37500273 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash gargle, used morning and night, and around sexual activities for 6 months.
Number of subjects: 40
Study 37500273 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan mouthwash gargle
Number of subjects: 40
Study 37500273 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash gargle
Number of subjects: 40
Study 37500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation programme (12-week home-based, tailored programme consisting of physical and/or nutritional and/or psychosocial interventions)
Number of subjects: 128
Study 37500274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation programme (12-week home-based, tailored programme)
Number of subjects: 128
Study 37500274 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 128
Study 37500277 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) and morphology
Number of subjects: 500
Study 37500277 — intervention group
Group type: COMPARATOR
Intervention: Morphology alone
Number of subjects: 500
Study 37500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 581
Study 37500339 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 581
Study 37500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 581
Study 37500612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance with intermittent 2-week courses of insulin every 3-months for 2-years
Number of subjects: 99
Study 37500612 — intervention group
Group type: COMPARATOR
Intervention: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance
Number of subjects: 99
Study 37500647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Interferon-gamma (IFN-γ)
Number of subjects: 26
Study 37500714 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo magnetic resonance spectroscopy (MRS) technique utilizing frequency-selective editing pulses
Number of subjects: 0
Study 37500926 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation (specifically hyperfractionated radiotherapy) for recurrent, inoperable nasopharynx cancer
Number of subjects: 60
Study 37500926 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation for glioma
Number of subjects: 60
Study 37500926 — intervention group
Group type: COMPARATOR
Intervention: Standard care for recurrent disease after previous radiotherapy
Number of subjects: 60
Study 37500930 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application targeting physical activity for 12 weeks
Number of subjects: 146
Study 37500930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smartphone application)
Number of subjects: 146
Study 37500950 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time Sister Circles® intervention (peer-based support group, 2 hours/week for 13 weeks)
Number of subjects: 172
Study 37500950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 37501016 — intervention group
Group type: EXPERIMENTAL
Intervention: gavo-cel (T cell receptor fusion construct) administered as a single agent (n=3) or after lymphodepletion (n=29)
Number of subjects: 32
Study 37501016 — intervention group
Group type: EXPERIMENTAL
Intervention: gavo-cel (T cell receptor fusion construct)
Number of subjects: 32
Study 37501020 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 192
Study 37501059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia (HHcy)
Number of subjects: 11189
Study 37501059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum level of total Hcy
Number of subjects: 11189
Study 37501063 — intervention group
Group type: EXPERIMENTAL
Intervention: 22510SS intervention (2 hours of outdoor activities, limit screen time to 2 hours, consume 5 servings of fruits and vegetables, 1 hour of physical activity, no sugar-sweetened beverages, reasonable sleep duration, regular supervision)
Number of subjects: 36
Study 37501063 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 37501078 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful Roles program
Number of subjects: 0
Study 37501102 — intervention group
Group type: COMPARATOR
Intervention: Information only (community health workers provide basic information on high blood pressure and salt consumption)
Number of subjects: 309
Study 37501102 — intervention group
Group type: EXPERIMENTAL
Intervention: Free low-sodium salt substitute (LSSS) with education on benefits
Number of subjects: 309
Study 37501172 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Melodies for Mums (M4M) online singing intervention, 6-week duration.
Number of subjects: 37
Study 37501180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threshold HCV treatment model at a syringe services program
Number of subjects: 29
Study 37501206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 413914
Study 37501206 — intervention group
Group type: COMPARATOR
Intervention: Occasional meat-eaters
Number of subjects: 413914
Study 37501206 — intervention group
Group type: COMPARATOR
Intervention: Pescatarians
Number of subjects: 413914
Study 37501206 — intervention group
Group type: COMPARATOR
Intervention: Regular meat-eaters
Number of subjects: 413914
Study 37501212 — intervention group
Group type: EXPERIMENTAL
Intervention: VLED (640 kcal/day) during 12 or 16 weeks, depending on baseline BMI < 40 or ≥ 40 kg/m²
Number of subjects: 0
Study 37501212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37501217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hand orthosis with task-oriented upper limb training for 12 weeks (3 weeks supervised, 9 weeks unsupervised)
Number of subjects: 15
Study 37501509 — intervention group
Group type: EXPERIMENTAL
Intervention: SURGICEL® Powder (SURGICEL®-P)
Number of subjects: 103
Study 37501632 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregiver interactions with nursing home staff
Number of subjects: 30
Study 37501632 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff management of resident behavioral symptoms
Number of subjects: 30
Study 37501632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home context
Number of subjects: 30
Study 37501632 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregiver knowledge of dementia
Number of subjects: 30
Study 37501632 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregiver strain
Number of subjects: 30
Study 37501632 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident experience
Number of subjects: 30
Study 37502272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootle Blast videogame intervention for upper limb functional exercise, played at home for 12 weeks.
Number of subjects: 4
Study 37502338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 9989
Study 37502338 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA test (mt-sDNA)
Number of subjects: 9989
Study 37502338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 9989
Study 37502424 — intervention group
Group type: EXPERIMENTAL
Intervention: Human probiotics and prebiotics
Number of subjects: 0
Study 37502424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37502440 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum UCA1
Number of subjects: 90
Study 37502440 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum WRAP53
Number of subjects: 90
Study 37502440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UCA1, WRAP53, and serum α-fetoprotein (AFP)
Number of subjects: 90
Study 37502622 — intervention group
Group type: EXPERIMENTAL
Intervention: AK0529 2 mg/kg bid
Number of subjects: 0
Study 37502622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37502622 — intervention group
Group type: EXPERIMENTAL
Intervention: AK0529
Number of subjects: 0
Study 37502721 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-calorie ketogenic diet (VLCKD)
Number of subjects: 20
Study 37503002 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro
Number of subjects: 30
Study 37503002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum
Number of subjects: 30
Study 37503002 — intervention group
Group type: COMPARATOR
Intervention: Duplicate meals
Number of subjects: 30
Study 37503152 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 67
Study 37503152 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 67
Study 37503157 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarker panel (kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1)
Number of subjects: 241
Study 37503157 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarker panel
Number of subjects: 241
Study 37503357 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a single fraction of 25 Gy
Number of subjects: 5
Study 37503561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-RBD IgG concentrations ≥1000 BAU/mL
Number of subjects: 636
Study 37503561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-RBD IgG concentrations ≥3000 BAU/mL
Number of subjects: 636
Study 37503561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid immunity group
Number of subjects: 636
Study 37503561 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ release post-SARS-CoV-2 peptide stimulation
Number of subjects: 636
Study 37503575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastic mouthwash
Number of subjects: 30
Study 37503575 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 30
Study 37503602 — intervention group
Group type: EXPERIMENTAL
Intervention: >20% reduction in NT-proBNP levels
Number of subjects: 3821
Study 37503602 — intervention group
Group type: EXPERIMENTAL
Intervention: >20% rise in NT-proBNP levels
Number of subjects: 3821
Study 37503602 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤20% change in NT-proBNP levels
Number of subjects: 3821
Study 37503629 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with layered plaques
Number of subjects: 533
Study 37503629 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with layered plaques
Number of subjects: 533
Study 37503629 — intervention group
Group type: COMPARATOR
Intervention: Layered plaques in men
Number of subjects: 533
Study 37503629 — intervention group
Group type: COMPARATOR
Intervention: Layered plaques in women
Number of subjects: 533
Study 37503661 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoberminogene rezmadenovec (XC001) administered via epicardial delivery
Number of subjects: 12
Study 37504371 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of alkaline phosphatase (AP)
Number of subjects: 210
Study 37504371 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor chemotherapy-induced tumor necrosis
Number of subjects: 210
Study 37504371 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of metastases at presentation
Number of subjects: 210
Study 37504371 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of erythrocyte sedimentation rate (ESR)
Number of subjects: 210
Study 37504555 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) for breast cancer
Number of subjects: 101
Study 37505106 — intervention group
Group type: EXPERIMENTAL
Intervention: SyMRI-based radiomic features at midtreatment
Number of subjects: 181
Study 37505106 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable radiomics models of maps acquired at midtreatment
Number of subjects: 181
Study 37505107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-standard group (FTV0 model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: COMPARATOR
Intervention: Standard group (FTV0 model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-standard group (∆FTV1 model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: COMPARATOR
Intervention: Standard group (∆FTV1 model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-standard group (∆FTV2 model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: COMPARATOR
Intervention: Standard group (∆FTV2 model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-standard group (multiple predictor model)
Number of subjects: 432
Study 37505107 — intervention group
Group type: COMPARATOR
Intervention: Standard group (multiple predictor model)
Number of subjects: 432
Study 37505117 — intervention group
Group type: COMPARATOR
Intervention: Ever smoking
Number of subjects: 576